β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

• US 10,000,523 B2
• Filed: 10/12/2017
• Issued: 06/19/2018
• Est. Priority Date: 03/06/2015
• Status: Active Grant

• Current Assignee: Atea Pharmaceuticals, Inc.
• Original Assignee: Atea Pharmaceuticals, Inc.
• Inventors: Sommadossi, Jean-Pierre, Moussa, Adel
• Primary Examiner(s): McIntosh, III, Traviss C
• Application Number:
  US15/782,628
• Publication Number:
  US 20180030081A1
• Time in Patent Office: 250 Days
• Field of Search: None
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07H 19/16 Purine radicals
• CPC Class Codes: C07H 19/20 with the saccharide radical esterified by phosphoric or polyphosphoric acids
• CPC Class Codes: C07H 19/207 the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Abstract

A compound of the structure:

or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

Claims

1. A pharmaceutical composition comprising an anti-HCV effective amount of a compound of the formula:

2. The pharmaceutical composition of claim 1, comprising an effective amount of a compound of the formula:

3. The pharmaceutical composition of claim 1, comprising an effective amount of a compound of the formula:

4. The pharmaceutical composition of claim 1, in a dosage form.

5. The pharmaceutical composition of claim 4, in an oral dosage form.

6. The pharmaceutical composition of claim 5, in a tablet.

7. The pharmaceutical composition of claim 5, in a capsule.

8. The pharmaceutical composition of claim 2, in a dosage form.

9. The pharmaceutical composition of claim 8, in an oral dosage form.

10. The pharmaceutical composition of claim 9, in a tablet.

11. The pharmaceutical composition of claim 9, in a capsule.

12. The pharmaceutical composition of claim 3, in a dosage form.

13. The pharmaceutical composition of claim 12, in an oral dosage form.

14. The pharmaceutical composition of claim 13, in a tablet.

15. The pharmaceutical composition of claim 13, in a capsule.

16. A pharmaceutical composition comprising an anti-HCV effective amount of a compound of the formula:

17. The pharmaceutical composition of claim 16, comprising an effective amount of a compound of the formula:

18. The pharmaceutical composition of claim 16, comprising an effective amount of a compound of the formula:

19. The pharmaceutical composition of claim 16, in a dosage form.

20. The pharmaceutical composition of claim 19, in an oral dosage form.

21. The pharmaceutical composition of claim 20, in a tablet.

22. The pharmaceutical composition of claim 20, in a capsule.

23. The pharmaceutical composition of claim 17, in a dosage form.

24. The pharmaceutical composition of claim 23, in an oral dosage form.

25. The pharmaceutical composition of claim 24, in a tablet.

26. The pharmaceutical composition of claim 24, in a capsule.

27. The pharmaceutical composition of claim 18, in a dosage form.

28. The pharmaceutical composition of claim 27, in an oral dosage form.

29. The pharmaceutical composition of claim 28, in a tablet.

30. The pharmaceutical composition of claim 28, in a capsule.